The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by distinct histological subtypes and a poor prognosis. Among these, the micropapillary pattern, typically observed ...

A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer. SIL-204 siRNA encapsulated in extended release ...

In the presence of invasive carcinoma, mucinous cystadenocarcinoma, the prognosis is similar to typical ductal adenocarcinoma of the pancreas which underscores the need to remove MCNs at the time of ...

Potential effect of the gut microbiome on tumour response to anti-cancer treatment in patients diagnosed with pancreatic ductal adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma ... liver, lung, oral, pancreatic, and prostate cancers are carcinomas. There are also variations in carcinoma cell ...

By Daniella Parra Lisata Therapeutics said results from Cohort A of its Phase 2 ASCEND trial showed complete responses in 6.2% of certepetide-treated patients, compared to 0% in the placebo group. The ...

Lisata Therapeutics (LSTA) and WARPNINE announced encouraging preliminary results from the Phase 1b/2a iLSTA trial evaluating certepetide, ...